S. Jones

发表

Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies

A. Tan, J. Bendell, J. Infante, 2014, British Journal of Cancer.

Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days.

H. Burris, P. Lorusso, J. Hodge, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter, Phase II Trial of Exemestane as Third-Line Hormonal Therapy of Postmenopausal Women With Metastatic Breast Cancer

L. Fehrenbacher, A. Consonni, B. Cooper, 1999 .

Phase I study of PF-04554878, a second-generation focal adhesion kinase (FAK) inhibitor, in patients with advanced solid tumors.

G. Shapiro, S. Shreeve, Philippe Bédard, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I dose-escalation study of NKP-1339 in patients with advanced solid tumors refractory to treatment.

D. V. Von Hoff, G. Weiss, J. Bendell, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors.

A. Razak, H. Burris, C. Bowen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies

Suzanne F. Jones, R. Neuwirth, L. Hart, 2017, Cancer Chemotherapy and Pharmacology.

Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study.

S. Morris, H. Wakelee, B. Sikic, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.

A. Tolcher, N. Le, D. Rasco, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.

Suzanne F. Jones, Yulei N. Wang, J. Bendell, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical activity of GW572016 in EGF10003 in patients with solid tumors.

David A. Smith, A. Stead, G. Wilding, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.

A. Tolcher, N. Le, D. Rasco, 2015 .

Phase II study of NK012 in relapsed small cell lung cancer.

J. Hainsworth, J. Bendell, H. Burris, 2011, Journal of Clinical Oncology.

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.

Y. Wang, J. Bendell, L. Camacho, 2014 .

Single agent gefitinib in poor performance status patients with previously untreated advanced non-small cell lung cancer: A Minnie Pearl Cancer Research Network phase II trial.

J. Hainsworth, H. Burris, M. Thomas, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009).

J. Hainsworth, H. Burris, N. Peacock, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors.

A. Stead, G. Wilding, H. Burris, 2004, Journal of Clinical Oncology.

Summary of results in patients with metastatic renal cell cancer (RCC) from phase I studies of RAD001 (everolimus).

J. Baselga, I. Judson, H. Burris, 2006, Journal of Clinical Oncology.

mTOR inhibitor everolimus (Ev) and IGFR inhibitor OSI-906 (OSI) for the treatment of patients (pts) with refractory metastatic colorectal cancer (mCRC): A Sarah Cannon Research Institute phase I trial.

L. Hart, J. Bendell, H. Burris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.